Editas Medicine, Inc. (EDIT) saw a decrease of 7.04% in aftermarket following the update in SEC filing. However, the last trading session concluded at $19.32 with an increase of 3.15%.
Recent Progress Announced – How is it?
EDIT announced updates regarding the recent progress of the company on 10th January 2022. In its BRILLIANCE research of EDIT-101, Editas Medicine has finished dosing of all adult cohorts. Moreover, preliminary EDIT-101 trial data showed a positive safety profile and promising clinical benefit signs, which were previously announced. Following a safety assessment by an independent data monitoring committee, the Company plans to begin treating the pediatric high-dose group this year.
Furthermore, in the second half of 2022, the company plans to release a clinical update on the BRILLIANCE trial, which will include safety and efficacy assessments on all patients. By the end of the year 2022, the company expects to have established registration trial criteria for EDIT-101.
Editas Medicine, Inc. (EDIT): What’s Next?
EDIT is creating a high-value pipeline of gene editing treatment candidates, powered by best-in-class next-generation technologies, including the efficient, high-precision, and SLEEK editing platform. With EDIT-101 in LCA10, the company achieved proof-of-concept in 2021, demonstrating the utility of the foundational in vivo approach in multiple ocular diseases.
In addition, EDIT hopes to receive preliminary clinical data from the ex vivo EDIT-301 program in sickle cell disease this year. Lastly, the company is also looking forward to moving the alpha-beta T cell oncology program.
Appointment of Dr. Jessica Hopfield – More About it
EDIT reported about the appointment of Dr. Jessica Hopfield on 20th December 2021. The company is happy to welcome Dr. Hopfield to the Board. Moreover, Dr. Hopfield helps to bring to Berkeley Lights crucial strategic understanding and a clear emphasis on achievement to push the unrivaled ability to comprehend cell biology. Not only this but Dr. Jessica has more than two decades of medical device, biotech, and pharmacological experience. Lastly, the team is certain that her enthusiasm for collaborating with businesses to bring new ideas to market will make her an invaluable asset.
